The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
المخرجات
Research outputs
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
Long-term, flexible therapy strategies are needed for chronic diseases like cardiovascular ailments, diabetes, and chronic kidney disease and they have to deal with patient heterogeneity, changing physiological states and privacy constraints. This research suggests a framework for privacy-preserving and personalized artificial intelligence that combines Federated Learning (FL), a Res-HyperTransformerNet deep prediction model, Personalized Multi-Agent Reinforcement Learning (PMARL) and Explainable Artificial Intelligence (XAI) for adaptive chronic disease management. The framework is structured with two main aims: (i) to create an accurate and privacy-aware predictive model for chronic disease risk using diverse data sources, and (ii) to permit adaptive, individual therapy optimization through multi-agent reinforcement learning. Federated learning is utilized to conduct the training of Res-HyperTransformerNet over distributed Internet of Medical Things (IoMT) nodes without the requirement of transferring raw patient data. The embeddings that are created from patient data are then passed on to a PMARL module, where several agents optimize therapy dimensions like medications, diet, physical activity, and mental health interventions independently. To make the clinical support more understandable, the SHAP-based explainability method is used for both predictive and decision-making parts. The framework is tested using two public datasets—the CDC Chronic Disease dataset and the UCI Chronic Kidney Disease Risk Factor dataset. The performance is measured by employing classification metrics (accuracy, precision, recall, F1-score, MCC) as well as reinforcement learning metrics (reward score, convergence steps, episode return) and federated system metrics (communication overhead, convergence rounds, and training time). The experiments indicate that the proposed framework demonstrated improved performance in terms of predictive accuracy and policy convergence speed compared to the baseline deep learning and reinforcement learning models, and at the same time it is more cost-effective when it comes to communication in a federated setting. This means that the proposed method suggests the potential of being a reproducible and open AI framework for adaptive chronic disease therapy management. The combination of ResNet and Transformer blocks, i.e., Federated Res-HyperTransformerNet, achieved strong performance in both datasets, namely CDC Chronic Disease (Dataset 1) and UCI CKD Risk Factor (Dataset 2). The obtained accuracy for Dataset 1 was 98.61% and for Dataset 2, it was 97.75%, under the conducted experimental settings.
Traditional anatomical resources like cadaveric dissection and professional atlases are the gold standard, but face constraints in cost and accessibility. The rapid integration of generative artificial intelligence (AI) in medical education offers new possibilities for custom anatomical illustration. Text-to-image AI generators provide an inexpensive and swift alternative for medical illustration. However, the anatomical fidelity and educational reliability of these models remain insufficiently validated. This study aimed to evaluate the accuracy of four prominent AI image generators in producing anatomically correct illustrations of the human heart, kidney, and brain. Four AI platforms-Copilot, Microsoft Designer, Gemini, and Freepik-were prompted to generate high-resolution, textbook-style illustrations of the heart (sternocostal view), kidney (coronal cross-section), and brain (lateral view). A total of 12 selected images were evaluated by a radiologist and two anatomists utilizing a structured 5-point Likert scale across five domains: textural realism, topological validity, morphometric accuracy, perspective and depth perception, and educational utility. Significant variability in performance was observed across platforms. Gemini consistently demonstrated superior performance, achieving perfect intraclass correlation coefficients (ICCs) and the highest ratings on complex topological tasks, including the representation of coronary vasculature and cortical sulci/gyri. Copilot showed high spatial accuracy in renal hilum organization. While all platforms showed high reliability and accuracy across broad morphological shapes (aortic arch, cerebral poles), accuracy declined sharply as anatomical complexity increased. AI-generated anatomical illustrations currently vary from medically indistinguishable to biologically impossible. While Gemini and Copilot show promise for supplemental educational use, the high frequency of hallucinated anatomical details in other platforms poses a risk for medical misinformation. The study underscores the necessity for expert supervision and for developing AI models trained on curated, peer-reviewed medical datasets.
Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular morbidity and end-stage renal disease. Renin-angiotensin-aldosterone system (RAAS) inhibitors, specifically angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are standard therapies for organ protection. However, uncertainty remains regarding their comparative efficacy and the safety of combination therapy. This systematic review and meta-analysis aimed to compare the efficacy of ACEIs versus ARBs in reducing cardiovascular and renal events in patients with T2DM and to assess the safety of dual blockade. PubMed, EMBASE, and Cochrane databases were searched for randomized controlled trials (RCTs) published up to 2025 comparing ACEIs, ARBs, or their combination against placebo or active controls in T2DM patients. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, and renal failure. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data were synthesized using frequentist pairwise and Bayesian network meta-analyses. Heterogeneity was explored via meta-regression, and trial sequential analysis (TSA) was used to assess the sufficiency of evidence. In total, 16 RCTs involving 47,406 participants were included. In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control. Network meta-analysis showed no statistically significant difference between ACEIs and ARBs (RR = 0.98, 95% CI = 0.88-1.09). Although ACEIs ranked slightly higher in probability for reducing all-cause mortality (surface under the cumulative ranking = 78% vs. 65%), this difference was not statistically significant. Dual blockade (ACEI + ARB) increased the risk of hyperkalemia (RR = 2.8) and acute kidney injury (RR = 1.7) without improving efficacy. Meta-regression identified baseline systolic blood pressure as a significant modifier of treatment benefit (p = 0.04). TSA indicated that the evidence for the RAAS blockade's benefit is conclusive. ACEIs and ARBs exhibit comparable efficacy in preventing cardiovascular and renal events in patients with T2DM, with a marginal mortality benefit favoring ACEIs. Dual blockade is associated with increased harm and is not recommended. Monotherapy with either agent remains the preferred strategy for organ protection.
ACE inhibitorsangiotensin receptor blockerstype 2 diabetesrenin-angiotensin-aldosterone system blockade
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a cornerstone of adult heart failure (HF) therapy and are increasingly prescribed off-label to children, yet pediatric outcomes have never been pooled. We searched PubMed/MEDLINE, Embase, Scopus, and Web of Science to 14 August 2026 for studies of any SGLT2 inhibitor in children or adolescents with HF and performed a single-arm meta-analysis of all exposed patients and a pairwise meta-analysis of the comparative studies with random-effects models. Nine studies contributed 599 exposed patients and 97 controls. Pooled rates were 3.8% (95% confidence interval [CI] 1.6-8.4) for mortality, 8.5% (6.2-11.5) for transplantation, 11.2% (8.2-15.1) for worsening HF, 0.2% (0.03-1.6) for ketoacidosis, 4.5% (1.2-14.9) for acute kidney injury, 3.7% (1.1-11.7) for urinary tract infection, and 4.1% (1.4-11.2) for discontinuation because of an adverse event. After initiation, left ventricular ejection fraction rose by 7.7 percentage points (3.6-11.8) and natriuretic peptide fell by 0.42 standard deviations (0.34-0.49). In the comparative synthesis (63 exposed, 97 unexposed), risk ratios were 0.80 (0.11-6.07) for mortality and 0.21 (0.03-1.68) for worsening HF; ejection fraction improved 3.34 percentage points more with SGLT2 inhibitors (0.22-6.46) whereas natriuretic peptide did not differ (standardized mean difference -0.09, -0.50 to 0.33).
SGLT2 inhibitorsheart failurepediatric heart failurechildren and adolescents
Frontiers in Pharmacology · vol. 17 · 1847011-1847011
Background Endothelial dysfunction driven by intermittent hypoxia (IH)-induced oxidative stress, nitric oxide depletion, and adhesion molecule upregulation underlies obstructive sleep apnea (OSA)-related cardiovascular complications. Vitamin D deficiency, which frequently coexists with OSA, may further amplify this endothelial injury through impaired endothelial nitric oxide synthase (eNOS) regulation and heightened renin-angiotensin-aldosterone system (RAAS) activity; however, the dose-dependent therapeutic potential of vitamin D3 on combined endothelial and renal outcomes in an IH model remains uncharacterized. Methods Fifty-six adult male Sprague-Dawley rats were allocated to seven groups: control, vitamin D-deficient (VDD), VDD with severe IH (SIH-VDD), and four supplementation subgroups receiving high-dose (37.5 μg/kg/day) or low-dose (25 μg/kg/day) cholecalciferol under severe or moderate IH for 14 days. Serum E-selectin, ICAM-1, ET-1, NO, and PCSK9 were quantified by ELISA. Renal histopathology was assessed on H&E sections by a blinded pathologist. Data were analyzed by one-way MANOVA, univariate ANOVA, and LSD post hoc tests (p < 0.05). Results The SIH-VDD group showed the most severe endothelial activation: peak E-selectin (4.92 ± 0.90 ng/mL), ICAM-1 (201.50 ± 21.55 ng/mL), ET-1 (5.31 ± 0.81 pg/mL), and PCSK9 (213.50 ± 14.71 ng/mL), with the lowest NO (14.88 ± 2.16 μmol/L; all p < 0.001 vs. control). High-dose supplementation produced substantial recovery across all markers; PCSK9 normalized to near-control (162.50 ng/mL) under severe IH. Low-dose supplementation yielded incomplete normalization. Renal histopathology revealed mild interstitial lymphocytic infiltration in IH-exposed groups, with proximal tubular vacuolisation exclusively in the SIH-VDD group and entirely absent in all supplemented groups. Glomerular architecture remained preserved throughout. Conclusion Vitamin D deficiency combined with IH upregulates endothelial dysfunction markers and induces renal tubular injury in an experimental OSA model. High-dose vitamin D 3 attenuates these changes dose- and severity-dependently, supporting its role as a pharmacological adjunct for OSA-associated endothelial and renal complications.
Micro-plastics (MPs) have become a constant source of pollution in freshwater bodies and increasingly becoming a threat to aquatic life. Chronic exposure to MPs has been linked to the inhibition of growth, deformations in digestive physiology, oxidative stress, and cellular injury. Current study was conducted on fish (Ctenopharyngodon idella) acclimatizing and exposing them to a 90-day dietary exposure to MPs. The growth performance indicators, that is, digestive enzymes, oxidative stress biomarkers, and DNA damages were measured in the pre- and post-dietary exposure to the MPs. There was a progressive decrease in the growth performance indicators such as highest increase in weight as found in 30% PVC group (6.95 ± 2.69 g) and the 30% PS group (2.91 ± 3.28 g) was far less as compared to the corresponding controls (18.8 ± 5.86 and 16.07 ± 5.32 g, respectively). The levels of catalase activity in the control fish kidney, skin, heart, brain, and gill tissues were significantly higher than in the exposed groups (p < 0.05), whereby superoxide dismutase activity were increased, an indication to the increased oxidative stress. Digestive enzyme reactions were tissue-specific, where lipase was the most sensitive, mainly in the stomach and liver, at the increased dosage. The frequency of micronuclei also increased in the erythrocytes of exposed fish, which proves that polymers caused concentration-dependent genotoxic damage. Hence, PVC and PS MPs had negative effects on C. idella whereby growth was affected, antioxidant status was disturbed, genotoxicity was augmented, digestive enzyme biomarkers were affected, and micro-nucleus frequency was increased. Further research is required on chronic exposure, histopathological changes, and the mechanisms of MPs toxicity at the molecular level.
Journal of King Saud University - Science · vol. 38 · 3852025-3852025
Lung cancer is the leading cause of cancer-related death in numerous countries worldwide. Given their severe side effects that can impact the patients’ quality of life, the current treatment approaches need more specific targeting to reduce chemotherapeutic toxicities. Cell-based targeted delivery has recently gained momentum as a promising platform for the delivery of anticancer drugs. As a new biotechnology platform, bacterial ghosts (BGs) have novel biomedical applications, including targeted drug delivery systems. In the current work, the BG of Streptococcus pneumoniae and Klebsiella pneumoniae ghosts were used as potential targeted-delivery agents for treating lung cancer cells. Bacterial ghosts of S. pneumoniae and K. pneumoniae were prepared using the most recent protocol (tween/acid). The doxorubicin (DOX) uploading was optimized by applying the required conditions to maximize loading capacity. We evaluated the DOX-loaded BGs’ antiproliferative and apoptotic effects on two lung cancer cell lines (H69A, A549) and one normal human embryonic kidney cell line (HEK293) in comparison to free BGs and DOX alone. We also tested the sustained release patterns for each formula. We predicted the mechanism of augmenting the actions of both systems by a protein-protein docking study. The preparation of well-formulated ghosts of both bacteria was successful and confirmed. The loading capacity was maximized to 31.2 ± 3.1% (n=3) for S. pneumoniae ghosts (SPG) and 28.8± 2.6% (n=3) for K. pneumoniae ghosts (KPG). The sustained release pattern of both SPG and KPG followed the Higuchi kinetic model, while Free DOX exhibited a rapid release pattern consistent with the first-order kinetic model. The antiproliferative activity using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay revealed the superiority of SPG loaded with DOX (SPG-DOX) over all other tested formulae (10.8% viability) on multi-drug-resistant lung cancer cells (H69A). The IC50s of SPG-Dox loaded were one-sixth and one-fifth of the IC50 of the Free DOX in H69A and A549, respectively, indicating more potency. The cell viability was 46.6% upon using Free DOX. In non-small cell lung cancer cells (A549), the SPG-DOX formula also showed superior antiproliferative activity (23.1% viability), as compared to control vehicles. SPG and KPG showed the highest safety toward the normal cell lines (HEK293), with more than 80% of cells surviving. Using H69A cells, KPG-DOX showed superior apoptotic activity (58.2%) over Free DOX, which achieved less than 20% cellular apoptosis. In A549 cells, SPG-DOX showed apoptotic activity of 57.7% compared to Free DOX. (32.5%). The docking study showed a strong binding interaction between a KPG surface protein (4HWM) and the overexpressed non-small cell lung cancer carcinoma receptor, epidermal growth factor receptor kinase domain (EGFR 2ITO), with a binding score (S) for the interaction of -63.94 kcal/mol. The interaction was -61.26 of SPG surface protein (3ZPP) with EGFR. The application of S. pneumoniae and K. pneumoniae BGs loaded with DOX represents a promising targeted drug delivery system for the treatment of lung cancer. The superior potency and safety of both systems warrant further investigation into their preclinical and clinical activities.
The continuous progression of cancerous severity due to the interaction of physical (ultraviolet radiation), chemical (smoking, mycotoxins, and heavy metals), and biological (microbial populations) carcinogens inspired scientists to develop a correlation between active therapeutic agents and cancer proliferation. This review highlights the molecular mechanism by which lycopene imparts its anticancerous role, focusing on clinical and animal trials to validate its effectiveness. The antioxidant profile of lycopene promotes anticancerous properties that reduce cancer prevalence by activating cell signaling pathways and gene expression (involved in cancer cell proliferation). Lycopene's anti-inflammatory properties suppresses the tumor growth and development-promoting pathways, such as the PI3K/Akt/mTOR pathway. The anticancer property of lycopene is also evidenced by its inhibitory potential of the Wnt/β-catenin signaling pathway that is involved in cancer cell modulation and propagation. Lycopene also suppresses and neutralizes oxidative stress and reactive oxygen species (ROS)-induced DNA damage, preventing gene mutation. Inflammation-induced cell death is mitigated by lycopene's anti-inflammatory potential that lowers the expression of interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Several clinical and randomized control trials have revealed the effect of lycopene supplementation in the management of cancer, including breast cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, skin cancer, oral cancer, liver cancer, gastric cancer, and kidney cancer, by lessening prostate-specific antigen (PSA) levels. These studies also accentuate certain limitations that need further trials to evaluate the long-term consequences of lycopene supplementations and their specific effective dose.
Frontiers in Pharmacology · vol. 16 · 1525529-1525529
Introduction: Gentamicin (GM) is a frequently used aminoglycoside for managing serious illnesses; nonetheless, renal complications limit its use. Bee venom (BV) is a biological toxin that exhibits anti-inflammatory and antioxidant activities. This study was designed to explore the mitigating effect of BV remediation on GM induced renal injury. Methods: Twenty male rats were divided into four groups (five rats each), namely, control (saline subcutaneously); BV group (1 mg/kg S/C twice weekly for 1 month); GM group (100 mg/kg i. p. for 1 week); and GM-BV group (the same aforementioned dosages of GM and BV, with GM administered in the last week for 4 weeks). Results and discussion: BV mitigated the GM-inflicted kidney damage, as evidenced by a substantial improvement in the renal function and oxidative state. In addition, a downregulation in the expression of inflammatory biomarkers (Casp-1, IL-6, TNF-α, and NF-κB/P65/P50) and an upregulation of oxidative stress marker expression (NRF2) were noticed. BV upregulated the expression of aquaporins (AQPs) and renal water channel proteins (AQP1 and AQP2), which are useful for the early detection of renal injury. Additionally, BV exposure exerted a mitigating effect on the apoptotic cascade, as evidenced by the downregulation of cleaved Caspase-3 (Casp-3) and cytochrome c (Cyto c). BV administration also led to an improvement in RBC, WBC, and platelet counts, along with enhanced Hb levels. Interestingly, BV could protect against GM triggered nephrotoxicity.
Diabetes mellitus (DM) is a growing public health concern globally, particularly in Saudi Arabia, where increasing prevalence is associated with significant morbidity. This study aimed to assess the prevalence of diabetes-related complications among patients in Riyadh and examine the impact of sociodemographic factors, comorbidities, and lifestyle habits on these complications. A cross-sectional study was conducted with 980 diabetic patients attending health centers in Riyadh from March to April 2023. Data were collected via a validated bilingual questionnaire that captured sociodemographic information, diabetes-related variables, comorbid conditions, lifestyle habits, and complications. Statistical analyses, including descriptive statistics, chi-square tests, and binary regression, were performed via SPSS to identify significant associations. A p-value less than 0.05 was considered significant for all comparisons. Among the participants (980), 38% (378) reported diabetes-related complications, primarily neuropathy (30%), retinopathy (25%), and cardiovascular diseases (20%). Complications were significantly associated with older age (p < 0.001) and longer diabetes duration (more than 5 years; p < 0.001). Individuals with hypertension, hyperlipidemia, heart disease, kidney disease, and obesity had significantly higher complication rates than those without these conditions (p < 0.05). The most pronounced association was observed in participants with heart disease (85% vs. 15%; RR = 1.506), highlighting the need for better management of these comorbidities. Consuming fruits and vegetables, milk, and regular exercise were inversely associated with the risk of complications (p < 0.05). Conversely, sugary drinks, white bread, sheesha/vaping, and inadequate sleep were linked to increased risk (p < 0.05), highlighting the protective role of healthy dietary and lifestyle habits. This study highlights the impact of sociodemographic factors and lifestyle choices-such as age, education, family history, comorbidities, and poor diet-on diabetes complications. While early detection and lifestyle interventions are vital, a cautious approach is needed when applying these findings to other regions, given differences in socioeconomic circumstances.
type 2 diabetesdiabetes complicationsdiabetic neuropathydiabetic retinopathy